Link to Enanta Home Page
About
About Us
Management Team
Board of Directors
Timeline
Pipeline
Overview
Hepatitis C Virus
Hepatitis B Virus
Respiratory Syncytial Virus
SARS-CoV-2
Chronic Spontaneous Urticaria
Science
Overview
Publications
Patients
Overview
Clinical Trials
Expanded Access Policy
Resources
Careers
Join Us
Culture
Core Values
Testimonials
Benefits
Collaborations
Partnering
Investors
Overview
Press Releases
Events & Presentations
Stock Information
Financials
ESG
Investor Resources
Contact Us
About
About
About Us
Management Team
Board of Directors
Timeline
Pipeline
Overview
Hepatitis C Virus
Hepatitis B Virus
Respiratory Syncytial Virus
SARS-CoV-2
Chronic Spontaneous Urticaria
Science
Overview
Publications
Patients
Overview
Clinical Trials
Expanded Access Policy
Resources
Careers
Join Us
Culture
Core Values
Testimonials
Benefits
Collaborations
Partnering
Investors
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Historic Price Lookup
Investment Calculator
Analyst Coverage
Financials
Quartlery Results
Annual Reports
SEC Filings
ESG
Overview
Environmental
Social
Governance
Investor Resources
Investor FAQs
Email Alerts
RSS Feed
Contact Us
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
MENU
About
About Us
Management Team
Board of Directors
Timeline
Pipeline
Overview
Hepatitis C Virus
Hepatitis B Virus
Respiratory Syncytial Virus
SARS-CoV-2
Chronic Spontaneous Urticaria
Science
Overview
Publications
Patients
Overview
Clinical Trials
Expanded Access Policy
Resources
Careers
Join Us
Culture
Core Values
Testimonials
Benefits
Collaborations
Partnering
Investors
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Historic Price Lookup
Investment Calculator
Analyst Coverage
Financials
Quartlery Results
Annual Reports
SEC Filings
ESG
Overview
Environmental
Social
Governance
Investor Resources
Investor FAQs
Email Alerts
RSS Feed
Contact Us